Figure 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

<p>Plasma concentration for copanlisib (BAY 80-6946). Plasma concentration of copanlisib (BAY 80-6946) was measured in samples from nine patients collected on cycle 1 day 15 before infusion (pre-dose) and at 0.5, 1, 2, 4, 6, 8, and 24 hours after infusion. Eight patients received copanlisib 45...

Mô tả đầy đủ

Đã lưu trong:

Chi tiết về thư mục
Tác giả chính:	Andre L. De Souza (22819921) (author)
Tác giả khác:	Matthew J. Hadfield (22819924) (author), Shaolei Lu (22819927) (author), Dragan J. Golijanin (22819930) (author), Roxanne Wood (22819933) (author), Jeannine Margolis (22819936) (author), Kate Anderson (22819939) (author), Adam J. Olszewski (15129834) (author), Sheldon L. Holder (22819942) (author), Wafik S. El-Deiry (15170575) (author), Rahul R. Aggarwal (15132918) (author), Anthony E. Mega (22819945) (author), Benedito A. Carneiro (15925723) (author)
Được phát hành:	2025
Những chủ đề:	Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase I Clinical Trials Prostate Cancer Small Molecule Agents DNA-reactive agents
Các nhãn:	Thêm thẻ Không có thẻ, Là người đầu tiên thẻ bản ghi này!

Figure 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Những quyển sách tương tự